Kayne Anderson Rudnick Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$734	–	970
2025 Q4	$734	Hold	14	–	–	﹤0.01%	904
2025 Q3	$907	Hold	14	–	–	﹤0.01%	892
2025 Q2	$681	Hold	14	–	–	﹤0.01%	965
2025 Q1	$476	Hold	14	–	–	﹤0.01%	909
2024 Q4	$551	Hold	14	–	–	﹤0.01%	931
2024 Q3	$658	Hold	14	–	–	﹤0.01%	918
2024 Q2	$756	Hold	14	–	–	﹤0.01%	882
2024 Q1	$954	Buy	+14	New	+$1K	﹤0.01%	848
2023 Q4	–	Sell	-14	Closed	-$635	–	970
2023 Q3	$635	Hold	14	–	–	﹤0.01%	775
2023 Q2	$786	Hold	14	–	–	﹤0.01%	768
2023 Q1	$633	Buy	+14	New	+$680	﹤0.01%	669

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CRSP Position: Q1 2026 in Review

Kayne Anderson Rudnick Investment Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 14 shares — an estimated $734 sold.

Kayne Anderson Rudnick Investment Management first reported a position in CRSP in Q1 2023 and held it in 11 quarters. The position peaked at $954 in Q1 2024. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Kayne Anderson Rudnick Investment Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 14 CRISPR Therapeutics shares in Q1 2026, an estimated $734.
Kayne Anderson Rudnick Investment Management first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 11 quarters.
Kayne Anderson Rudnick Investment Management's CRISPR Therapeutics position peaked at $954 in Q1 2024.
492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2026, filed 14 May 2026.